Shop by goal
Popular compounds
Research resources
Recently viewed
Survodutide (BI 456906): A Research Guide to the GLP-1 / Glucagon Dual Agonist
Short answer: survodutide (BI 456906) is a GLP-1 + glucagon dual agonist from Boehringer Ingelheim and Zealand Pharma, given once weekly. The glucagon arm makes it as much a liver drug as a weight drug — it holds U.S. FDA Breakthrough Therapy status for the liver disease MASH, and the Phase 3 SYNCHRONIZE-1 obesity trial met both primary endpoints and cut liver fat by up to ~63%. It has no marketing authorisation anywhere as of mid-2026. New-U does not sell survodutide. Part of our next obesity-research wave overview.
Plain-English summary. Survodutide is an unapproved, investigational drug. Breakthrough Therapy designation speeds FDA review — it is not an approval. The FDA, MHRA and EMA have not authorised survodutide. This page is general information, not legal or medical advice; do not use unapproved compounds on people.
What survodutide actually is
Survodutide (developmental code BI 456906 ) is a synthetic peptide dual agonist of the GLP-1 and glucagon receptors, given as a once-weekly subcutaneous injection. It was discovered at Zealand Pharma and licensed to Boehringer Ingelheim, which leads its global development and commercialisation. Molecular and trial detail is indexed under PubMed: survodutide / BI 456906.
Why the glucagon arm is the story
Adding glucagon to GLP-1 changes what the drug does :
This is the same dual logic behind the glucagon arm of retatrutide — except retatrutide adds GIP on top, whereas survodutide stays a focused GLP-1/glucagon pairing aimed squarely at weight and liver.
The MASH angle
Because the glucagon arm pulls fat out of the liver, survodutide is being developed for MASH (metabolic dysfunction-associated steatohepatitis — the serious, fibrosing form of fatty liver disease) as well as obesity. The U.S. FDA granted survodutide Breakthrough Therapy designation for non-cirrhotic MASH with moderate-to-advanced fibrosis in September 2024. Its liver programme runs under the LIVERAGE Phase 3 studies.
The trial evidence
The SYNCHRONIZE-1 obesity results were published in the New England Journal of Medicine . Topline weight-loss magnitude and full secondary endpoints should be read from the primary publication rather than summarised here as a single headline number, because trial design and estimands matter.
How survodutide compares
Survodutide and research compounds
Survodutide is a proprietary Boehringer Ingelheim / Zealand molecule and is not catalogued by research-compound suppliers. New-U does not sell survodutide. The closest established research reference that also carries a glucagon arm is the triple agonist:
Each ships as a sealed, lyophilised reference peptide verified to >99% HPLC purity with a per-batch Certificate of Analysis — research use only, not for human consumption .
Frequently Asked Questions
What is survodutide? A GLP-1 + glucagon dual agonist (BI 456906) from Boehringer Ingelheim and Zealand Pharma, dosed once weekly, developed for obesity and MASH.
Is survodutide approved? No. As of mid-2026 it has no marketing authorisation; it is in Phase 3. Its MASH Breakthrough Therapy status speeds review but is not approval.
How is it different from semaglutide? It adds glucagon-receptor agonism, which raises energy expenditure and mobilises liver fat — a weight-and-liver drug.
What did the trials show? SYNCHRONIZE-1 (Phase 3 obesity) met both primary endpoints and cut liver fat up to ~63%; Phase 2 MASH data showed fibrosis improvement.
Can I buy survodutide for research? No — it is proprietary. New-U catalogues the glucagon-arm reference retatrutide instead. Research use only.
Related Reading
Primary sources & further reading
External links are provided for research reference only; New-U is not affiliated with the cited organisations and links carry no endorsement either way.
From the Lab - Peptides on LinkedIn & Facebook
Lab-Verified Glucagon-Arm Research Reference
New-U Research Compounds catalogues retatrutide — the triple agonist whose glucagon arm parallels survodutide’s — plus semaglutide and tirzepatide, as sealed 10-vial packs of lyophilised reference peptide, independently verified by Janoshik and Freedom Diagnostics for >99% HPLC purity, with a per-batch Certificate of Analysis. Research use only — not for human consumption.
Research-grade · >99% HPLC purity · COA per lot
Buy research peptides from New-U Research Compounds
Lab-verified by Janoshik Analytical (RP-HPLC + ESI-MS), sealed vials, discreet tracked worldwide shipping. For laboratory research use only — not for human consumption.
PRECISION. PURITY. PERFORMANCE.
Research peptides at >99% HPLC-verified purity, third-party tested by Janoshik Analytical & Freedom Diagnostics, with Certificates of Analysis published per released batch. Supplied strictly for laboratory research use.
Shop
Research
Support
Ways to Pay
Shop by goal
Shop by compound
Shop by region
Research use only (RUO). All products are sold strictly for laboratory and research purposes — not for human or veterinary consumption. Purchasers must be 21 or older.
All rights reserved. Copyright of New-U held with Hilxera Distribution Services LLC 2026.
Website & business operated by Hilxera Distribution Services LLC. Registered in Wyoming, ID: 2026-001928701.
© 2026 New-U Research Compounds · new-u.io